SocialPicks Sentiment:
** v.s.
other stocks
|
This Quarter's Sentiment:
|
|
|
SocialPicks Community
Access Pharma Report: MuGard Sales, Pipeline Offer Big Upside Potential
ACCP
|
|
|
<> Access Pharma (OTC: ACCP) (ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment called MuGard is cleared for marketing in the U.S., Europe, and other key global markets for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining). In addition, the Company is developing earlier stage compounds in its pipeline and has an oral cobalamin nanopolymer drug delivery technology which has demonstrated positive results ...
|
Access Pharma (OTC:ACCP): MuGard Poised for Blockbuster Sales
ACCP
|
|
|
<> On 7/23/09, Access Pharma (OTC:ACCP) (ACCP.OB) announced that its European partner, SpePharm, is collecting data from a post-approval marketing study of MuGard in head and neck cancer patients undergoing radiation treatment in the UK showing prevention of oral mucositis (OM). In a multi-center study expected to enroll a total of 280 patients, patients are provided with seven weeks of MuGard therapy, and begin using MuGard one week prior to radiation treatment and then throughout the subsequent six weeks of planned therapy. The first 140 patients being treated in this assessment study hav<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Access Pharma (OTC:ACCP): Deep Pipeline, Shallow Valuation
ACCP
|
|
|
<> Access Pharma (OTC:ACCP)(ACCP.OB) is an emerging bio-pharmaceutical company which is focusing on the development of a late-stage, diversified oncology pipeline in addition to a treatment for a common side effect of some cancer treatments known as mucositis (painful sores in the mouth and GI mucosal lining) which has already received FDA 510(k) marketing clearance and European CE Mark approval. On 7/13/09, Access announced that it would be among the LifeTech Capital Group companies presenting at Jesup & Lamont’s 2009 Growth Stock & National Sales Conference to be held at the Waldorf Astoria<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Lixte Biotech (OTC:LIXT): Key 2H09 Catalysts Await
ACCP
|
|
|
<> Since I first wrote about Lixte Biotech (OTC:LIXT) at <font> BioMedReports.com in early April </font> , the Company has provided an update on its development-stage cancer drug discovery operations as part of a SEC 10Q filing in mid-May for 1Q09. LIXT.OB was originally founded as a diagnostics company in 2005 evaluating biomarkers (indicators of disease at the molecular level), but has shifted its focus to cancer drug discovery research that is primarily focused on the development of compounds for malignancies with few effective treatment options – such as certain types of brain cancer<><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><><>...
|
Access Pharmaceuticals Inc.
ACCP
|
|
|
 Since I last wrote about Access Pharma (OTC:ACCP) two weeks ago as a cancer biotech call option trade <> , the Company has issued two updates on its clinical development pipeline and two updates for MuGard - which is an oral rinse product for the management of a common side effect of many cancer therapies, mucositis. In late May, Access announced that MuGard was launched in Germany, Italy, UK, Greece, and the Nordic countries by its European commercial partner, SpePharm, with expected launches in North America, Asia, and other regions slated for later this year. On 6/10/09, A...
|
|
ROCK-STAR INVESTORS
|
|
POPULAR STOCKS
|
|
TODAY'S HEADLINES
|
|
TODAY'S TOP PICKS
|
|
|
| StreetInsider.com on ACCP |
Visit streetinsider.com
More Resources
|
About Access Pharmaceuticals Inc.
- Answers.com
